Objective: LncRNA ITGB2-AS1 has been found to play important roles in the occurrence and development of human solid tumors. However, its role in hematological diseases, especially acute myeloid leukemia (AML), remains unclear. The aim of this study was to identify the expression pattern of ITGB2-AS1 in AML patients and to further explore its clinical significance.
Methods: ITGB2-AS1 expression was analyzed in public datasets (including TCGA and GSE63270) and further validated in a cohort of 109 AML patients by real-time quantitative PCR (RT-qPCR).
Results: The level of ITGB2-AS1 was up-regulated among two independent cohorts (TCGA, P<0.05; GSE63270, P<0.05), which was confirmed by the data from 109 AML patients enrolled in this study (P<0.05). Clinically, high ITGB2-AS1 expression was associated with older age (P=0.023) and lower complete remission (CR) rate (P=0.005). Multivariate analysis identified that high ITGB2-AS1 expression was an independent prognostic factor not only for CR rate (P=0.027) but also for overall survival (OS) time (P=0.011), and ITGB2-AS1 was positively correlated with ITGB2 expression in both TCGA (r=0.74, P<0.001) and clinical data detected in this study (r=0.881, P<0.001). High ITGB2 expression was also associated with older age (P=0.02) and lower CR rate (P=0.020). Moreover, high ITGB2 expression predicted worse OS (P=0.028).
Conclusion: ITGB2-AS1 is overexpressed in AML and predicts poor prognosis in AML patients.
题目: 长链非编码RNA ITGB2-AS1过表达预测急性髓系白血病的不良预后.
目的: 确定ITGB2-AS1在AML患者中的表达水平，并进一步探讨其临床意义.
方法: 本研究在公共数据集（包括TCGA和GSE63270）中分析ITGB2-AS1表达水平，并使用实时定量PCR（RT-qPCR）在109名AML患者队列中进一步验证.
结果: ITGB2-AS1表达水平在两个独立队列中上调（TCGA，P<0.05；GSE63270，P<0.05），并经本研究纳入的AML患者队列证实（P<0.05）。临床上，ITGB2-AS1高表达与较大的年龄（P=0.023）和较低的完全缓解（CR）率（P=0.005）相关。多变量分析发现，高ITGB2-AS1表达是CR率（P=0.027）和总体生存时间（OS）（P=0.011）的独立预后因素，ITGB2-AS1在TCGA数据集（r=0.74，P<0.001）和本研究患者数据中（r=0.881，P<0.001）均与ITGB2表达正相关。高ITGB2表达也与较大年龄（P=0.02）和较低CR率（P=0.020）相关。高ITGB2表达预测更短的OS（P=0.028）.
结论: ITGB2-AS1在AML中过表达并预测AML的不良预后.